We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01674205
First Posted: August 28, 2012
Last Update Posted: December 15, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Rochester
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
August 23, 2012
August 28, 2012
December 15, 2015
September 2012
June 2013   (Final data collection date for primary outcome measure)
  • Area under the curve (AUC) of nasal virus shedding after vaccine dose as assessed by liquid titration of nasal secretions on Madin Darby Canine Kidney (MDCK) cells [ Time Frame: Measured through Day 9 ]
  • Development of serum antibody as assessed by either HAI or microneutralization (MN) assays [ Time Frame: Measured through Day 56 ]
Same as current
Complete list of historical versions of study NCT01674205 on ClinicalTrials.gov Archive Site
  • Development of a significant increase in nasal secretion hemagglutinin (HA)-specific antibody assessed by enzyme-linked immunosorbent assay (ELISA) [ Time Frame: Measured through Day 56 ]
  • Detection of influenza-specific immunoglobulin G (IgG) or immunoglobulin A (IgA) secreting B cells assessed by antibody secreting cells (ASC) assay [ Time Frame: Measured at Day 7 ]
  • Development of greater than 200 influenza-specific interferon-gamma-secreting cells per million lymphocytes as assessed by enzyme-linked immunospot assay (ELISPOT) [ Time Frame: Measured at Day 28 ]
  • Development of a significant increase in nasal secretion hemagglutinin (HA)-specific antibody assessed by ELISA [ Time Frame: Measured through Day 56 ]
  • Detection of influenza-specific immunoglobulin G (IgG) or immunoglobulin A (IgA) secreting B cells assessed by antibody secreting cells (ASC) assay [ Time Frame: Measured at Day 7 ]
  • Development of greater than 200 influenza-specific interferon-gamma-secreting cells per million lymphocytes as assessed by enzyme-linked immunospot assay (ELISPOT) [ Time Frame: Measured at Day 28 ]
Not Provided
Not Provided
 
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)
This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.

Influenza A viruses are widely distributed in nature and exist as many different subtypes. Pandemics of influenza can occur, and vaccine development is focused on those subtypes that are predicted to represent the greatest pandemic threat to the human population. This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic LAIVs in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.

Three vaccines will be evaluated: the licensed seasonal LAIV, with a focus on the H3N2 component; the H9N2 G9/AA ca vaccine, which is among the most immunogenic of the candidate pandemic LAIVs evaluated to date; and the H2N3 MO 2066/AA ca vaccine, which is among the least immunogenic of the candidate pandemic LAIVs evaluated to date. The seasonal LAIV will be evaluated in an outpatient setting, while the other two vaccines will be evaluated in an inpatient setting. In each setting, some participants will receive a placebo vaccine.

Study participants will be assigned to one of four groups. Participants who are seronegative to both H9N2 G9/AA ca and H2N3 MO 2006/AA ca viruses will be randomly assigned to receive one of those vaccines (Group 1: H9N2 G9/AA ca; Group 2: H2N3 MO 2006/AA ca) or placebo (Group 4) and will remain in an inpatient isolation facility. Participants who are seronegative to the H3 component of seasonal LAIV will be randomly assigned to receive either seasonal vaccine (Group 3) or placebo (Group 4) and will be followed as outpatients.

All participants will remain in the study for 56 days. Participants in the inpatient arms will be admitted on Day -2, will receive study vaccine on Day 0, and will undergo a basic history, physical examination, and nasal wash each day until discharge. On some study days, inpatient participants will undergo a blood collection and/or a nasal swab; at the screening visit and on Day -1 or Day -2, participants will give a urine sample.

Participants in the outpatient arms will receive study vaccine on Day 0 and will have study visits on Days 1, 2, 3, 4, 5, 6, 7, 14, 28, and 56. On Days 1 through 7, participants will undergo a basic history, physical examination, and nasal wash. On some visits, participants may undergo a blood collection and/or a nasal swab; at the screening visit and on Day -1, participants will give a urine sample. Unused blood or nasal wash samples will be stored and may be used in future research studies.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Influenza, Human
  • Biological: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)
  • Biological: A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)
  • Biological: 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
  • Biological: Vaccine placebo (Leibovitz-15 [L-15])
  • Biological: Vaccine placebo (FluMist®)
  • Experimental: Group 1 (Inpatient, H2N3 MO 2006/AA ca)
    Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
    Intervention: Biological: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)
  • Experimental: Group 2 (Inpatient, H9N2 G9/AA ca)
    Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
    Intervention: Biological: A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)
  • Experimental: Group 3 (Outpatient, seasonal LAIV [FluMist®])
    2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
    Intervention: Biological: 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
  • Placebo Comparator: Group 4 (Both inpatient and outpatient, placebo)
    Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
    Interventions:
    • Biological: Vaccine placebo (Leibovitz-15 [L-15])
    • Biological: Vaccine placebo (FluMist®)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator
  • Agree to storage of blood specimens for future research
  • Available for the duration of the trial. For the inpatient component of the study, participants must be willing and able to remain within the Isolation Unit for the specified duration of confinement. For the outpatient component of the study, participants must be willing and able to make daily outpatient follow-up visits as specified by the protocol.
  • Willingness to participate in the study as evidenced by signing the informed consent document
  • Female participants must agree to use effective birth control methods for the duration of the study (for example, pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; intrauterine device; abstinence from heterosexual intercourse; or surgical sterilization). All female participants will be considered being of child-bearing potential except those who have undergone hysterectomy and those in whom menopause occurred at least 1 year prior to the study.

Exclusion Criteria:

  • Pregnancy as determined by a positive human choriogonadotropin (beta-HCG) test
  • Currently breastfeeding
  • Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urine testing. Clinically significant alanine aminotransferase (ALT) levels, as determined by the Principal Investigator, will be exclusionary at baseline, prior to vaccination.
  • Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and cooperate with the study protocol
  • Previous enrollment in an H2 or H9 influenza vaccine trial or in any study of an avian influenza vaccine
  • For the inpatient arm, seropositive to the H2N3 influenza A virus or the H9N2 influenza A virus (serum HAI titer >1:8). For the outpatient arm, seropositive to the H3N2 component of seasonal LAIV (serum hemagglutination inhibition [HAI] titer greater than 1:8).
  • Positive urine drug toxicology test indicating narcotic use/dependency
  • Have medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
  • Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial or would render the subject unable to comply with the protocol
  • History of anaphylaxis
  • Allergy to oseltamivir as determined by subject report
  • Current diagnosis of asthma or reactive airway disease (within the past 2 years)
  • History of Guillain-Barré Syndrome
  • Positive ELISA and confirmatory Western blot tests for human immunodeficiency virus-1 (HIV-1)
  • Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for hepatitis C virus (HCV)
  • Positive hepatitis B virus surface antigen (HBsAg) by ELISA
  • Known immunodeficiency syndrome
  • Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination
  • Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination
  • History of a surgical splenectomy
  • Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination
  • Current smoker unwilling to stop smoking for the duration of the study

    • A current smoker includes anyone stating he/she currently smokes any amount of a tobacco product
    • The decision to exclude a potential participant is determined by medical history and a clinician's clinical judgment based on the physical examination
    • After admission to the unit, nicotine patches will be provided to current smokers who request them for the inpatient portion of the study
  • Travel to the Southern Hemisphere within 14 days prior to study vaccination
  • Travel on a cruise ship within 14 days prior to study vaccination
  • Receipt of another investigational vaccine or drug within 30 days prior to study vaccination
  • Allergy to eggs or egg products
Sexes Eligible for Study: All
18 Years to 42 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01674205
URMC 12-001
No
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
University of Rochester
Principal Investigator: John Treanor, MD University of Rochester
National Institute of Allergy and Infectious Diseases (NIAID)
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP